Kotak Institutional Equities says worst of price war in diag

The brokerage has a 'sell' call on Dr Lal with a target price of ₹1,740, implying a potential downside of over 30 percent. Meanwhile, it has a 'reduce' call on Metropolis with a target price of ₹1,350, indicating an over 7 percent downside.

Related Keywords

Hyderabad , Andhra Pradesh , India , Mumbai , Maharashtra , Delhi , Lal Pathlabs , Orange Health , Metropolis Healthcare , Whatsapp Channels , Market , Stocks , Stock Markets , Healthcare , Diagnostics , Diagnostic Stocks , Diagnostic Sector , Dr Lal Pathlabs , Dr Lal Pathlabs Stock , Dr Lal Pathlabs Shares , Dr Lal Pathlabs Share Price , Dr Lal Pathlabs News , Kotak On Dr Lal Pathlabs , Metropolis Healthcare Stock , Metropolis Healthcare Shares , Metropolis Healthcare Share Price , Metropolis Healthcare News , Kotak On Metropolis Healthcare ,